|Last Price||Today's Change||52-Week Range||Trading Volume|
|48.81||0.99 (+2.07%)||19.67 - 51.99||697.4 thousand (Below Avg)|
Market data as of 3:59PM 07/31/15. Quotes are delayed by at least 15 min.
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
06/16/2015 9:00 AM ET